| Bioactivity | Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis[1][2]. |
| Target | CSF-1 |
| In Vivo | Lacnotuzumab 中和食蟹猴重组和血清衍生形式的 CSF-1，但它不识别啮齿动物或兔的 CSF-1[2]。 |
| Name | Lacnotuzumab |
| CAS | 1831128-32-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kuemmel S, et, al. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Jan 1;28(1):106-115. [2]. Pognan F, et, al. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442. |